Unilever — Private Cards#

CONFIDENTIAL TO UNILEVER. Y1 cards distributed at start of Y1 solo prep. Y2 cards distributed at start of Y2 solo prep. Do not share contents with other participants unless the facilitator explicitly permits.

---

Y1 Cards#

Card Y1-A: Ice Cream Separation — The Bid Book Just Got Thinner#

The Ice Cream separation is publicly tracking toward a dual-track spin/IPO completion by year-end. The private reality is messier. Two of the three private-equity bidders who were running parallel auction processes have walked in the last six weeks — one citing dairy-input volatility and frozen-distribution capex, the other unwilling to underwrite Ben & Jerry's litigation overhang at any price. The remaining bidder is signaling a number roughly 15% below the floor your bankers presented to the board in Q4. A clean spin is still executable, but proceeds would flow as stock rather than the cash return your buyback program is sized around. Fernandez has not yet told the Board that the auction track is effectively dead. Trian is being briefed next week.

What this signals: Your largest strategic action of the Fernandez era is wobbling on execution, not strategy. The Y1 question is whether to absorb the slip quietly, accelerate the spin to reset the narrative, or use the moment to redirect capital toward a different defining move.

---

Card Y1-B: Beauty & Wellbeing — Nutrafol Is Hitting a Ceiling, Liquid I.V. Is Not#

Internal trackers show Nutrafol monthly active subscribers plateaued in Q4 2025 after three years of compounding growth — competitive entry from Hims and a wave of AI-formulated DTC hair-wellness brands has cut new-customer acquisition efficiency by roughly a third. Liquid I.V., by contrast, is running materially ahead of plan in both club channel and international expansion (Mexico, UK launches outperforming). K18 integration is on track but synergy capture is slower than the deal model. The Beauty & Wellbeing leadership team is internally split on whether to make a third major premium acquisition this year — a K-beauty platform target has been in diligence since November — or consolidate around the existing three.

What this signals: Beauty acceleration is your highest-conviction growth lever publicly, but the underlying signal is uneven. The Y1 question is whether to press into another acquisition while the Ice Cream proceeds are uncertain, or hold fire and prove out integration first.

---

Y2 Cards#

Card Y2-A: Ben & Jerry's — The Board Is About to Sue You#

Ben & Jerry's independent board has retained outside counsel and is preparing to file suit against Unilever, alleging the separation process and the parent company's recent governance interventions violate the 2000 acquisition agreement protecting the subsidiary's social mission. The filing is expected within 60 days and will be public. Discovery would surface internal communications about brand-purpose recalibration that would be uncomfortable for both Fernandez and the prior Schumacher administration. Trian's representative on the Unilever board has privately signaled willingness to support a forced sale of Ben & Jerry's to a values-aligned buyer (a B-Corp ice cream platform has expressed interest) if it accelerates resolution — but framing matters. A divestiture under litigation duress reads very differently than a strategic portfolio simplification.

What this signals: A latent governance dispute is about to become public, and your activist board member is offering a path that solves the legal problem but compounds the narrative problem. The Y2 question is whether to preempt, settle, fight, or divest — and how the choice interacts with whatever else you committed to in Y1.

---

Card Y2-B: India — A Two-Year Window Before the Local Champion Arrives#

Hindustan Unilever's India team has flagged that Reliance-backed Tira and a Tata-consortium beauty platform are both within 18 months of launching AI-personalized premium personal care lines aimed directly at the urban-affluent segment HUL has owned for a decade. Their cost structure — domestic manufacturing, AI-accelerated formulation, Jio distribution — undercuts HUL's premium tier by 30–40% at comparable claims. HUL is requesting an out-of-cycle capital allocation to pull forward AI-formulation R&D investment, expand the Lakmé and Ponds premium tiers, and lock in two-year exclusive supply agreements with three Indian dermatology DTC platforms before the competitive entry hits. The ask is material but absorbable.

What this signals: Your single most valuable emerging-market position has a closing window. The Y2 question is whether to fund the defense aggressively now while you still have first-mover capital advantage, or trust scale and brand to absorb the competitive entry.

---

Document Version: Project Threshold V8.1 — Unilever Private Cards Last Updated: May 2026